Castle Biosciences to Participate at the Canaccord Genuity 41st Annual Growth Conference

Rhea-AI Summary

Castle Biosciences (Nasdaq: CSTL) announced that CEO Derek Maetzold will present at the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021, at 3:30 p.m. ET. The presentation will be available via a live audio webcast on the company’s website, with a replay accessible for two weeks post-event.

Castle Biosciences focuses on dermatologic diagnostics, providing genomic information that informs treatment decisions, particularly for melanoma and other skin cancers. Their innovative tests are designed to aid physicians in making personalized treatment plans.

Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today announced that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the Canaccord Genuity 41^st Annual Growth Conference on Wednesday, Aug. 11, 2021, at 3:30 p.m. Eastern time.

A live audio webcast of the company’s presentation will be available by visiting Castle Biosciences’ website at https://ir.castlebiosciences.com/events-presentations/default.aspx. A replay of the webcast will be available for two weeks following the conclusion of the live broadcast.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a commercial-stage dermatologic diagnostics company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently offers tests for patients with cutaneous melanoma (DecisionDx^®-Melanoma, DecisionDx^®-CMSeq), cutaneous squamous cell carcinoma (DecisionDx^®-SCC), suspicious pigmented lesions (myPath® Melanoma, DecisionDx^® DiffDx™-Melanoma) and uveal melanoma (DecisionDx^®-UM, DecisionDx^®-PRAME and DecisionDx^®-UMSeq). For more information about Castle’s gene expression profile tests, visit www.CastleTestInfo.com.

Castle also has active research and development programs for tests in other dermatologic diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate to severe psoriasis, atopic dermatitis and related conditions. Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix. Additionally, in May of 2021, Castle acquired the myPath Melanoma laboratory in Salt Lake City.

For more information, visit www.CastleBiosciences.com.

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, myPath Melanoma, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210728005155/en/

FAQ

When will Castle Biosciences present at the Canaccord Genuity 41st Annual Growth Conference?

Castle Biosciences will present on August 11, 2021, at 3:30 p.m. Eastern time.

Where can I watch the live presentation of CSTL at the conference?

The live presentation can be accessed on Castle Biosciences’ website.

What is the focus of Castle Biosciences as a dermatologic diagnostics company?

Castle Biosciences provides personalized genomic information to inform treatment decisions for skin cancer and other dermatologic diseases.

What types of tests does Castle Biosciences offer?

Castle offers tests for cutaneous melanoma, squamous cell carcinoma, and other skin-related conditions.

Is there a replay available for Castle Biosciences' presentation?

Yes, a replay of the presentation will be available for two weeks after the live event.